Vanguard Group Inc. Grows Holdings in Kenvue Inc. (NYSE:KVUE)

Vanguard Group Inc. grew its position in Kenvue Inc. (NYSE:KVUE) by 0.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 218,543,705 shares of the company’s stock after acquiring an additional 1,636,741 shares during the period. Vanguard Group Inc. owned about 11.40% of Kenvue worth $4,665,908,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of KVUE. LPL Financial LLC lifted its position in shares of Kenvue by 4.9% during the 4th quarter. LPL Financial LLC now owns 2,064,405 shares of the company’s stock valued at $44,075,000 after buying an additional 96,030 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Kenvue during the fourth quarter worth $14,779,000. Sei Investments Co. lifted its holdings in Kenvue by 1.0% during the fourth quarter. Sei Investments Co. now owns 2,207,060 shares of the company’s stock valued at $47,121,000 after purchasing an additional 20,802 shares in the last quarter. Mizuho Securities USA LLC lifted its holdings in Kenvue by 46.3% during the fourth quarter. Mizuho Securities USA LLC now owns 181,712 shares of the company’s stock valued at $3,880,000 after purchasing an additional 57,524 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Kenvue in the fourth quarter valued at about $1,269,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Piper Sandler increased their target price on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. UBS Group lowered their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Evercore ISI began coverage on Kenvue in a research report on Monday. They set an “in-line” rating and a $25.00 price target for the company. Finally, Barclays decreased their price objective on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average target price of $23.85.

Kenvue Stock Up 0.3 %

KVUE stock opened at $23.38 on Tuesday. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm has a market cap of $44.68 billion, a PE ratio of 44.10, a PEG ratio of 2.62 and a beta of 1.25. The firm’s 50 day moving average price is $22.13 and its 200-day moving average price is $22.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, equities research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were given a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.51%. Kenvue’s payout ratio is currently 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.